An interventional study of LARIAT Suture Delivery Device in Atrial Appendage, sponsored by AtriCure, Inc.. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-09.
Sponsored by AtriCure, Inc. · Not applicable, Interventional, and Basic science
Evaluate the safety and effectiveness of the LARIAT Suture Delivery device in excluding the left atrial appendage in 100 patients.
The objective of this study is to evaluate the safety and effectiveness of the SentreHEART suture delivery system for the exclusion of the left atrial appendage in up to 100 treated patients.
AtriCure, Inc. is the lead sponsor of 31 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
LAA exclusion with the LARIAT Suture Delivery Device
Device: LARIAT Suture Delivery Device
LAA exclusion procedure
Rate of device related serious adverse events
Time frame: 30 days
Percent of patients with complete exclusion of the LAA measured with TEE
Time frame: 90 days
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AtriCure, Inc.